Current Environment: Production

Jaymin Upadhyay | Education

Undergraduate School

West Virginia University

Morgantown, WV

Graduate School

Boston University

Boston, MA

Fellowship

McLean Hospital

Belmont, MA

Jaymin Upadhyay | Publications

  1. Current insights in ultra-rare adenylosuccinate synthetase 1 myopathy - meeting report on the First Clinical and Scientific Conference. 3 June 2024, National Centre for Advancing Translational Science, Rockville, Maryland, the United States of America. Orphanet J Rare Dis. 2024 Nov 26; 19(1):438. View Current insights in ultra-rare adenylosuccinate synthetase 1 myopathy - meeting report on the First Clinical and Scientific Conference. 3 June 2024, National Centre for Advancing Translational Science, Rockville, Maryland, the United States of America. Abstract

  2. Characterization of pain and somatization and its relationship with psychopathology in early onset psychosis. J Psychiatr Res. 2024 Nov; 179:77-82. View Characterization of pain and somatization and its relationship with psychopathology in early onset psychosis. Abstract

  3. Focused Ultrasound-Mediated Disruption of the Blood-Brain Barrier for AAV9 Delivery in a Mouse Model of Huntington's Disease. Pharmaceutics. 2024 May 24; 16(6). View Focused Ultrasound-Mediated Disruption of the Blood-Brain Barrier for AAV9 Delivery in a Mouse Model of Huntington's Disease. Abstract

  4. Phenotyping Pain in Patients With Fibrous Dysplasia/McCune-Albright Syndrome. J Clin Endocrinol Metab. 2024 Feb 20; 109(3):771-782. View Phenotyping Pain in Patients With Fibrous Dysplasia/McCune-Albright Syndrome. Abstract

  5. Implications of Inflammatory Processes on a Developing Central Nervous System in Childhood-Onset Systemic Lupus Erythematosus. Arthritis Rheumatol. 2024 Mar; 76(3):332-344. View Implications of Inflammatory Processes on a Developing Central Nervous System in Childhood-Onset Systemic Lupus Erythematosus. Abstract

  6. Characterization of central manifestations in patients with Niemann-Pick disease type C. Genet Med. 2024 03; 26(3):101053. View Characterization of central manifestations in patients with Niemann-Pick disease type C. Abstract

  7. Peripheral Pain Captured Centrally: Altered Brain Morphology on MRI in Small Fiber Neuropathy Patients With and Without an SCN9A Gene Variant. J Pain. 2024 Mar; 25(3):730-741. View Peripheral Pain Captured Centrally: Altered Brain Morphology on MRI in Small Fiber Neuropathy Patients With and Without an SCN9A Gene Variant. Abstract

  8. Case report: Chronic pain in a pediatric patient with late-onset pompe disease. Front Pain Res (Lausanne). 2023; 4:1244609. View Case report: Chronic pain in a pediatric patient with late-onset pompe disease. Abstract

  9. A pilot investigation of muscle integrity in patients with ADSSL1 myopathy using electrical impedance myography. Muscle Nerve. 2023 Nov; 68(5):775-780. View A pilot investigation of muscle integrity in patients with ADSSL1 myopathy using electrical impedance myography. Abstract

  10. Synthetic CT Assessment of Lesions in Children With Rare Musculoskeletal Diseases. Pediatrics. 2023 08 01; 152(2). View Synthetic CT Assessment of Lesions in Children With Rare Musculoskeletal Diseases. Abstract

  11. The experience of living with Niemann-Pick type C: a patient and caregiver perspective. Orphanet J Rare Dis. 2023 05 20; 18(1):120. View The experience of living with Niemann-Pick type C: a patient and caregiver perspective. Abstract

  12. Pharmacological Interventions Targeting Pain in Fibrous Dysplasia/McCune-Albright Syndrome. Int J Mol Sci. 2023 Jan 29; 24(3). View Pharmacological Interventions Targeting Pain in Fibrous Dysplasia/McCune-Albright Syndrome. Abstract

  13. Diminished muscle integrity in patients with fibrodysplasia ossificans progressiva assessed with at-home electrical impedance myography. Sci Rep. 2022 12 03; 12(1):20908. View Diminished muscle integrity in patients with fibrodysplasia ossificans progressiva assessed with at-home electrical impedance myography. Abstract

  14. Continuing the conversation around opioid use disorder and post-traumatic stress disorder comorbidity. Lancet Psychiatry. 2022 08; 9(8):e37-e38. View Continuing the conversation around opioid use disorder and post-traumatic stress disorder comorbidity. Abstract

  15. Case Report: The Imperfect Association Between Craniofacial Lesion Burden and Pain in Fibrous Dysplasia. Front Neurol. 2022; 13:855157. View Case Report: The Imperfect Association Between Craniofacial Lesion Burden and Pain in Fibrous Dysplasia. Abstract

  16. Case Report: A Neuro-Ophthalmological Assessment of Vision Loss in a Pediatric Case of McCune-Albright Syndrome. Front Med (Lausanne). 2022; 9:857079. View Case Report: A Neuro-Ophthalmological Assessment of Vision Loss in a Pediatric Case of McCune-Albright Syndrome. Abstract

  17. Childhood maltreatment and its role in the development of pain and psychopathology. Lancet Child Adolesc Health. 2022 03; 6(3):195-206. View Childhood maltreatment and its role in the development of pain and psychopathology. Abstract

  18. Proteomics based markers of clinical pain severity in juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2022 Jan 15; 20(1):3. View Proteomics based markers of clinical pain severity in juvenile idiopathic arthritis. Abstract

  19. Targeting neurological abnormalities in lysosomal storage diseases. Trends Pharmacol Sci. 2022 06; 43(6):495-509. View Targeting neurological abnormalities in lysosomal storage diseases. Abstract

  20. Neurocircuitry basis of the opioid use disorder-post-traumatic stress disorder comorbid state: conceptual analyses using a dimensional framework. Lancet Psychiatry. 2022 01; 9(1):84-96. View Neurocircuitry basis of the opioid use disorder-post-traumatic stress disorder comorbid state: conceptual analyses using a dimensional framework. Abstract

  21. A multidisciplinary assessment of pain in juvenile idiopathic arthritis. Semin Arthritis Rheum. 2021 08; 51(4):700-711. View A multidisciplinary assessment of pain in juvenile idiopathic arthritis. Abstract

  22. Pain Phenotypes in Rare Musculoskeletal and Neuromuscular Diseases. Neurosci Biobehav Rev. 2021 05; 124:267-290. View Pain Phenotypes in Rare Musculoskeletal and Neuromuscular Diseases. Abstract

  23. Suppressed prefrontal cortex oscillations associate with clinical pain in fibrodysplasia ossificans progressiva. Orphanet J Rare Dis. 2021 01 30; 16(1):54. View Suppressed prefrontal cortex oscillations associate with clinical pain in fibrodysplasia ossificans progressiva. Abstract

  24. Altered Brain Network Connectivity Underlies Persistent Post-Traumatic Headache following Mild Traumatic Brain Injury in Youth. J Neurotrauma. 2021 06 15; 38(12):1632-1641. View Altered Brain Network Connectivity Underlies Persistent Post-Traumatic Headache following Mild Traumatic Brain Injury in Youth. Abstract

  25. Mechanisms Underlying Unconscious Processing and Their Alterations in Post-traumatic Stress Disorder: Neuroimaging of Zero Monetary Outcomes Contextually Framed as "No Losses" vs. "No Gains". Front Neurosci. 2020; 14:604867. View Mechanisms Underlying Unconscious Processing and Their Alterations in Post-traumatic Stress Disorder: Neuroimaging of Zero Monetary Outcomes Contextually Framed as "No Losses" vs. "No Gains". Abstract

  26. Implications of the putamen in pain and motor deficits in complex regional pain syndrome. Pain. 2020 03; 161(3):595-608. View Implications of the putamen in pain and motor deficits in complex regional pain syndrome. Abstract

  27. Enhancing Choice and Outcomes for Therapeutic Trials in Chronic Pain: N-of-1 + Imaging (+ i). Trends Pharmacol Sci. 2020 02; 41(2):85-98. View Enhancing Choice and Outcomes for Therapeutic Trials in Chronic Pain: N-of-1 + Imaging (+ i). Abstract

  28. Delineating conditions and subtypes in chronic pain using neuroimaging. Pain Rep. 2019 Jul-Aug; 4(4):e768. View Delineating conditions and subtypes in chronic pain using neuroimaging. Abstract

  29. Longitudinal Evaluation of Pain, Flare-Up, and Emotional Health in Fibrodysplasia Ossificans Progressiva: Analyses of the International FOP Registry. JBMR Plus. 2019 Aug; 3(8):e10181. View Longitudinal Evaluation of Pain, Flare-Up, and Emotional Health in Fibrodysplasia Ossificans Progressiva: Analyses of the International FOP Registry. Abstract

  30. Reward and aversion processing in patients with post-traumatic stress disorder: functional neuroimaging with visual and thermal stimuli. Transl Psychiatry. 2018 11 02; 8(1):240. View Reward and aversion processing in patients with post-traumatic stress disorder: functional neuroimaging with visual and thermal stimuli. Abstract

  31. The role of fMRI in drug development. Drug Discov Today. 2018 02; 23(2):333-348. View The role of fMRI in drug development. Abstract

  32. The Expansion of Heterotopic Bone in Fibrodysplasia Ossificans Progressiva Is Activin A-Dependent. J Bone Miner Res. 2017 Dec; 32(12):2489-2499. View The Expansion of Heterotopic Bone in Fibrodysplasia Ossificans Progressiva Is Activin A-Dependent. Abstract

  33. A critical evaluation of validity and utility of translational imaging in pain and analgesia: Utilizing functional imaging to enhance the process. Neurosci Biobehav Rev. 2018 Jan; 84:407-423. View A critical evaluation of validity and utility of translational imaging in pain and analgesia: Utilizing functional imaging to enhance the process. Abstract

  34. Detection of central circuits implicated in the formation of novel pain memories. J Pain Res. 2016; 9:671-681. View Detection of central circuits implicated in the formation of novel pain memories. Abstract

  35. Test-retest reliability of evoked heat stimulation BOLD fMRI. J Neurosci Methods. 2015 Sep 30; 253:38-46. View Test-retest reliability of evoked heat stimulation BOLD fMRI. Abstract

  36. Multimodal assessment of nervous and immune system responses following sciatic nerve injury. Pain. 2013 Dec; 154(12):2782-2793. View Multimodal assessment of nervous and immune system responses following sciatic nerve injury. Abstract

  37. Parallel buprenorphine phMRI responses in conscious rodents and healthy human subjects. J Pharmacol Exp Ther. 2013 Apr; 345(1):41-51. View Parallel buprenorphine phMRI responses in conscious rodents and healthy human subjects. Abstract

  38. Pain facilitation brain regions activated by nalbuphine are revealed by pharmacological fMRI. PLoS One. 2013; 8(1):e50169. View Pain facilitation brain regions activated by nalbuphine are revealed by pharmacological fMRI. Abstract

  39. Pharmacological modulation of brain activity in a preclinical model of osteoarthritis. Neuroimage. 2013 Jan 01; 64:341-55. View Pharmacological modulation of brain activity in a preclinical model of osteoarthritis. Abstract

  40. Decision-making using fMRI in clinical drug development: revisiting NK-1 receptor antagonists for pain. Drug Discov Today. 2012 Sep; 17(17-18):964-73. View Decision-making using fMRI in clinical drug development: revisiting NK-1 receptor antagonists for pain. Abstract

  41. Modulation of CNS pain circuitry by intravenous and sublingual doses of buprenorphine. Neuroimage. 2012 Feb 15; 59(4):3762-73. View Modulation of CNS pain circuitry by intravenous and sublingual doses of buprenorphine. Abstract

  42. Default-mode-like network activation in awake rodents. PLoS One. 2011; 6(11):e27839. View Default-mode-like network activation in awake rodents. Abstract

  43. Imaging drugs with and without clinical analgesic efficacy. Neuropsychopharmacology. 2011 Dec; 36(13):2659-73. View Imaging drugs with and without clinical analgesic efficacy. Abstract

  44. A procedural framework for good imaging practice in pharmacological fMRI studies applied to drug development #1: processes and requirements. Drug Discov Today. 2011 Jul; 16(13-14):583-93. View A procedural framework for good imaging practice in pharmacological fMRI studies applied to drug development #1: processes and requirements. Abstract

  45. A procedural framework for good imaging practice in pharmacological fMRI studies applied to drug development #2: protocol optimization and best practices. Drug Discov Today. 2011 Aug; 16(15-16):671-82. View A procedural framework for good imaging practice in pharmacological fMRI studies applied to drug development #2: protocol optimization and best practices. Abstract

  46. Direct optic nerve pulvinar connections defined by diffusion MR tractography in humans: implications for photophobia. Hum Brain Mapp. 2012 Jan; 33(1):75-88. View Direct optic nerve pulvinar connections defined by diffusion MR tractography in humans: implications for photophobia. Abstract

  47. Awake rat pharmacological magnetic resonance imaging as a translational pharmacodynamic biomarker: metabotropic glutamate 2/3 agonist modulation of ketamine-induced blood oxygenation level dependence signals. J Pharmacol Exp Ther. 2011 Mar; 336(3):709-15. View Awake rat pharmacological magnetic resonance imaging as a translational pharmacodynamic biomarker: metabotropic glutamate 2/3 agonist modulation of ketamine-induced blood oxygenation level dependence signals. Abstract

  48. Alterations in brain structure and functional connectivity in prescription opioid-dependent patients. Brain. 2010 Jul; 133(Pt 7):2098-114. View Alterations in brain structure and functional connectivity in prescription opioid-dependent patients. Abstract

  49. Robust, unbiased general linear model estimation of phMRI signal amplitude in the presence of variation in the temporal response profile. J Magn Reson Imaging. 2010 Jun; 31(6):1445-57. View Robust, unbiased general linear model estimation of phMRI signal amplitude in the presence of variation in the temporal response profile. Abstract

  50. Evaluation of novel drugs using fMRI in early-phase clinical trials: safety monitoring. Drug Discov Today. 2010 Aug; 15(15-16):684-9. View Evaluation of novel drugs using fMRI in early-phase clinical trials: safety monitoring. Abstract

  51. A key role of the basal ganglia in pain and analgesia--insights gained through human functional imaging. Mol Pain. 2010 May 13; 6:27. View A key role of the basal ganglia in pain and analgesia--insights gained through human functional imaging. Abstract

  52. A fMRI evaluation of lamotrigine for the treatment of trigeminal neuropathic pain: pilot study. Pain Med. 2010 Jun; 11(6):920-41. View A fMRI evaluation of lamotrigine for the treatment of trigeminal neuropathic pain: pilot study. Abstract

  53. Improved characterization of BOLD responses for evoked sensory stimuli. Neuroimage. 2010 Feb 01; 49(3):2275-86. View Improved characterization of BOLD responses for evoked sensory stimuli. Abstract

  54. Noninvasive mapping of human trigeminal brainstem pathways. Magn Reson Med. 2008 Nov; 60(5):1037-46. View Noninvasive mapping of human trigeminal brainstem pathways. Abstract

  55. A 'BOLD' experiment in defining the utility of fMRI in drug development. Neuroimage. 2008 Aug 15; 42(2):461-6. View A 'BOLD' experiment in defining the utility of fMRI in drug development. Abstract

  56. Effective and structural connectivity in the human auditory cortex. J Neurosci. 2008 Mar 26; 28(13):3341-9. View Effective and structural connectivity in the human auditory cortex. Abstract

  57. Diffusion properties of NAA in human corpus callosum as studied with diffusion tensor spectroscopy. Magn Reson Med. 2007 Nov; 58(5):1045-53. View Diffusion properties of NAA in human corpus callosum as studied with diffusion tensor spectroscopy. Abstract

  58. Diffusion tensor spectroscopy and imaging of the arcuate fasciculus. Neuroimage. 2008 Jan 01; 39(1):1-9. View Diffusion tensor spectroscopy and imaging of the arcuate fasciculus. Abstract

  59. Function and connectivity in human primary auditory cortex: a combined fMRI and DTI study at 3 Tesla. Cereb Cortex. 2007 Oct; 17(10):2420-32. View Function and connectivity in human primary auditory cortex: a combined fMRI and DTI study at 3 Tesla. Abstract